After the data release, they have lockup time from two week to 6 month, here is from the K-8:
he total outstanding number of March 2010 Warrants and December 2010 Warrants as of the date of this filing is 110,643,000.
The total outstanding face value of warrants to purchase Senior Unsecured Convertible Promissory Notes E due March 9, 2013 (the "Debt Warrants") is $2.0 million as of the date of this filing. Debt Warrants may be exercised by the holder up until a date that is six months after the public release of survival data from the Company's AGENDA clinical trial. A holder of Debt Warrants can exercise them for cash or on a cashless basis.
The total outstanding amount of Purchase Rights and Consent Rights resulting from the Company's financing in April 2009 are $13.2 million as of the date of this filing. These rights may only be exercised for cash. The rights can be exercised by the holder up until a date that is two weeks after the public release of survival data from the Company's AGENDA clinical trial. If exercised, a holder would receive a Senior Unsecured Convertible Promissory Note F due March 9, 2013.
The Company currently expects to release the survival data in April 2011. Sales of common stock underlying the Debt Warrants and the Purchase and Consent Rights are subject to a 6-month lockup from the date of exercise or conversion.
AI
